Search Results
Sep 08, 2026, 09:36 ET SciBase receives additional order from Castle Biosciences, advancing the collaboration
$0.6 million or approximately MSEK 5. In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration project, which aims to predict relapses in atopic dermatitis (AD),
More news about: SciBase
Sep 08, 2026, 09:30 ET SciBase receives additional order from Castle Biosciences, advancing the collaboration
$0.6 million or approximately MSEK 5. In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration project, which aims to predict relapses in atopic dermatitis (AD),
More news about: SciBase
Aug 20, 2026, 07:00 ET Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present
More news about: Castle Biosciences, Inc.
Aug 17, 2026, 07:00 ET Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually
More news about: Castle Biosciences, Inc.
Jul 30, 2026, 16:05 ET Castle Biosciences Reports Second Quarter 2026 Results
FRIENDSWOOD, Texas, July 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30,
More news about: Castle Biosciences, Inc.
Jul 22, 2026, 07:00 ET Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present
More news about: Castle Biosciences, Inc.
Jul 14, 2026, 16:30 ET Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
FRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York
More news about: Castle Biosciences, Inc.
Jul 09, 2026, 07:00 ET Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second
More news about: Castle Biosciences, Inc.
Jun 25, 2026, 16:30 ET DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
FRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter study in
More news about: Castle Biosciences, Inc.
Jun 23, 2026, 07:00 ET Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been
More news about: Castle Biosciences, Inc.
Jun 19, 2026, 07:00 ET Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its
More news about: Castle Biosciences, Inc.
Jun 16, 2026, 07:00 ET Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
FRIENDSWOOD, Texas, June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its TissueCypher® Barrett's Esophagus
More news about: Castle Biosciences, Inc.
May 13, 2026, 07:00 ET Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present
More news about: Castle Biosciences, Inc.
May 12, 2026, 07:00 ET Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner
More news about: Castle Biosciences, Inc.
May 06, 2026, 16:05 ET Castle Biosciences Reports First Quarter 2026 Results
FRIENDSWOOD, Texas, May 6, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31,
More news about: Castle Biosciences, Inc.
May 05, 2026, 07:00 ET Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
MayFRIENDSWOOD, Texas, May 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its participation in a series of initiatives throughout
More news about: Castle Biosciences, Inc.
May 04, 2026, 07:00 ET New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
FRIENDSWOOD, Texas, May 4, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data generated by researchers at Mayo Clinic
More news about: Castle Biosciences, Inc.
Apr 21, 2026, 07:00 ET Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
FRIENDSWOOD, Texas, April 21, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on its DecisionDx-Melanoma test
More news about: Castle Biosciences, Inc.
Apr 15, 2026, 07:00 ET Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first
More news about: Castle Biosciences, Inc.
Apr 10, 2026, 07:00 ET Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received the 2026 USA TODAY Top Workplaces
More news about: Castle Biosciences, Inc.
Mar 27, 2026, 09:05 ET Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
FRIENDSWOOD, Texas, March 27, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD)
More news about: Castle Biosciences, Inc.
Nov 07, 2025, 02:27 ET SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million
leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase and Castle Biosciences ("Castle") (NASDAQ: CSTL) have expanded their collaboration and license agreement and entered into a separate loan agreement. The two companies first entered into the collaboration
More news about: SciBase
Sep 23, 2025, 02:13 ET SciBase receives initial order for clinical study from Castle Biosciences
June 16th, 2025, SciBase has entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The initial collaboration project is to develop a test that predicts flares in patients diagnosed with
More news about: SciBase